Aclaris Therapeutics (ACRS) Interest Expenses (2014 - 2026)

Aclaris Therapeutics' Interest Expenses history runs 13 years deep, the most recent figure standing at $14.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 1878.57% year-over-year to $14.7 million in Q1 2026; TTM through Mar 2026 was $14.7 million, a 1878.57% increase from a year earlier, with the FY2025 full-year figure at $197.1 million, down 12.15% from the prior year.
• Interest Expenses advanced to $14.7 million in Q1 2026 per ACRS's latest filing, from $8.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $184.7 million in Q4 2022 and bottomed at $14000.0 in Q4 2023.
• The 5-year median for Interest Expenses is $3.7 million (2023), against an average of $16.2 million.
• Across the five-year window, Interest Expenses tumbled 99.99% in 2023 and jumped 21100.0% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $184.7 million in 2022, then tumbled by 99.99% to $14000.0 in 2023, then soared by 21100.0% to $3.0 million in 2024, then soared by 189.66% to $8.6 million in 2025, then soared by 70.77% to $14.7 million in 2026.
• Per Business Quant, the three latest ACRS Interest Expenses figures stand at $14.7 million (Q1 2026), $8.6 million (Q4 2025), and $2.2 million (Q3 2025).